文献速递主动脉外科心外重症与机械循环支持

重组因子VIIa在急性A型主动脉夹层修复术中的应用:NORCAAD多中心倾向评分匹配报告

Recombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-08-24

本研究基于NORCAAD数据库,采用多中心倾向评分匹配回顾性设计,比较急性A型主动脉夹层术后使用重组因子VIIa(rFVIIa)与未使用患者的结局。匹配后各120例,rFVIIa组输血更多、再探查止血更常见,但院内死亡、术后卒中及肾脏替代治疗风险未显著增加。

要点

  • rFVIIa用于急性A型主动脉夹层术后难治性出血未显著增加卒中、肾脏替代治疗或死亡风险。
  • rFVIIa组输血量及再探查止血率更高,提示该组出血负担更重。
  • 倾向评分匹配后rFVIIa与院内死亡、卒中、肾脏替代治疗的OR均无统计学显著性。

核心结论

  • 在倾向评分匹配的急性A型主动脉夹层手术队列中,因大出血使用rFVIIa与卒中、肾脏替代治疗或死亡风险显著增加无关。

研究设计与样本

  • 多中心、倾向评分匹配、回顾性研究,基于NORCAAD数据库。
  • rFVIIa使用信息可获取者761例,其中171例接受rFVIIa治疗。
  • 成功匹配120例rFVIIa治疗患者与120例对照。

临床怎么用

  • 对于急性A型主动脉夹层术后难治性大出血,在充分评估后可考虑使用rFVIIa,但需注意该组患者出血负担更重且再探查率更高。
  • 使用rFVIIa时仍应密切监测卒中、肾功能及出血相关并发症。

局限性

  • 回顾性研究设计,存在未测量混杂可能。
  • 原文未报告匹配后样本的基线特征均衡性细节。
  • 原文未报告rFVIIa具体剂量及给药时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgery for acute type A aortic dissection (ATAAD) is often complicated by excessive bleeding. Recombinant factor VIIa (rFVIIa) effectively treats refractory bleeding associated with ATAAD surgery; however, adverse effects of rFVIIa in these patients have not been fully assessed. Here we evaluated rFVIIa treatment in ATAAD surgery using the Nordic Consortium for Acute Type A Aortic Dissection (NORCAAD) database. METHODS: This was a multicenter, propensity score-matched, retrospective study. Information about rFVIIa use was available for 761 patients, of whom 171 were treated with rFVIIa. We successfully matched 120 patients treated with rFVIIa with 120 controls. Primary endpoints were in-hospital mortality, postoperative stroke, and renal replacement therapy (RRT). Survival data were presented using Kaplan-Meier estimates. RESULTS: Compared with controls, patients treated with rFVIIa received more transfusions of packed red blood cells (median, 9.0 U [4.0-17.0 U] vs 5.0 U [2.0-11.0 U]; P = .008), platelets (4.0 U [2.0-8.0 U] vs 2.0 U [1.0-4.4 U]; P <.001), and fresh frozen plasma (8.0 U [4.0-18.0 U] vs 5.5 U [2.0-10.3 U]; P = .01) underwent reexploration for bleeding more often (31.0% vs 16.8%; P = .014); and had greater 24-hour chest tube output (1500 L [835-2500 mL] vs 990 mL [520-1720 mL]). Treatment with rFVIIa was not associated with significantly increased rates of in-hospital mortality (odds ratio [OR], 0.74; 95% confidence interval [CI], 0.34-1.55; P = .487), postoperative stroke (OR, 1.75; 95% CI, 0.82-3.91; P = .163), or RRT (OR, 1.18; 95% CI, 0.48-2.92; P = .839). CONCLUSIONS: In this propensity-matched cohort study of patients undergoing ATAAD surgery, treatment with rFVIIa for major bleeding was not associated with a significantly increased risk of stroke, RRT, or mortality.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Zindovic I, Sjögren J, Ahlsson A, et al. Recombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection. J Thorac Cardiovasc Surg. 2017. PMID: 28967418. doi:10.1016/j.jtcvs.2017.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。